Regarding other subtypes, 21/21 patients with AITL, 10/12 patients with PTCL-NOS, and 4/4 patients with ALK− ALCL, 6/7 NK/T had a best response of CR/PR (Table 2) during the follow-up period. This evidence concerns the gene ALK and angioimmunoblastic T-cell lymphoma.